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dominant cystoid macular dystrophy on chromosome 7p. The letter by Monaghan et al. (1997) in the January
Hum Mol Genet 3:299–302 1997 issue of the Journal, discussing testing for Prader-
Lathrop GM, Lalouel JM, Julier C, Ott J (1984) Strategies for
Willi (PWS) and Angelman (AS) syndromes, raised sev-multipoint linkage analysis in humans. Proc Natl Acad Sci
eral interesting points. Essentially the issues related toUSA 81:3443–3446
the sequence of diagnostic testing for PWS/AS (cytoge-Leach RJ, Banga SS, Ben-Othame K, Chughtai S, Clarke R,
netics, methylation testing, and FISH), considering theDaiger SP, Kolehmainen J, et al (1996) Report of the Third
pick-up rate of abnormal results and the costs involved.International Workshop on Human Chromosome 8 Map-
Several others have addressed this topic (Chu et al. 1994;ping. Cytogenet Cell Genet 75:71–84
Mintz-Hittner H, Ferrell RE, Borda RP, Justice J Jr (1984) Smith et al. 1995; Young 1995; American Society of
Atypical vitelliform macular dystrophy in a 5-generation Human Genetics/American College of Medical Genetics
family. Br J Ophthalmol 68:199–207 Test and Technology Transfer Committee 1996; Erdel
Small KW, Syrquin M, Mellen L, Gehrs K (1996) Mapping of et al. 1996; Kubota et al. 1996), but Monaghan et al.
autosomal dominant cone degeneration to chromosome (1997) are the ﬁrst to include discussion of the costs of
17p. Am J Ophthalmol 121:13–18 testing. We would like to (a) relate our 12-mo experience
Small KW, Weber JL, Roses A, Lennon F, Vance JM, Pericak- of performing diagnostic tests for a referred group of
Vance MA (1992) North Carolina macular dystrophy is patients suspected to have PWS or AS and (b) review
localized to 6q14-q16.2. Am J Hum Genet Suppl 51:A34
the logistics and costs of multiple testing.Sohocki MM, Sullivan LS, Harrison WR, Sodergen EJ, Elder
Our department of cytogenetics is well established,FFB, Weinstock G, Tanase S, et al (1997) Human glutamate
with a specimen receptionist, an excellent blood labora-pyruvate transaminase (GPT): localization to 8q24.3, cDNA
tory, and staff dedicated to FISH. Our newly institutedand genomic sequences, and polymorphic sites. Genomics
molecular laboratory has one staff scientist who per-40:247–252
forms DNA extractions and the methylation test. A staffStone EM, Nichols BE, Kimura AE, Weingeist TA, Drack A,
cytogeneticist (A.S.) consults with patients/referring cli-Shefﬁeld VC (1994) Clinical features of a Stargardt-like
dominant progressive macular dystrophy with genetic link- nicians, obtains clinical information, and coordinates
age to chromosome 6q. Arch Ophthalmol 112:765–772 the whole process. Within the one department, the
Weber BHF, Vogt G, Pruett RC, Stohr H, Felbor U (1994) whole is well accommodated, with adjacent laboratories
Mutations in the tissue inhibitor of metalloproteinases-3 and ofﬁces. All concerned work closely together.
(TIMP3) in patients with Sorsby’s fundus dystrophy. Nat Cytogenetic analysis on high-resolution chromosomes
Genet 8:352–356 (HRC) had been performed for many years in our labo-
Welch SG (1972) Quantitative differences between the human ratory. FISH for PWS/AS was piloted in 1991 and re-
red cell glutamate-pyruvate transaminase phenotypes. Hum
placed HRC in 1993. We began methylation analysis in
Hered 22:190–197
1995. Our aim was to obtain a result on the index caseWijesuriya SD, Evans K, Jay MR, Davison C, Weber BHF, Bird
from a single blood collection, using a coordinated ap-AC, Bhattacharya SS, et al (1996) Sorsby’s fundus dystrophy
proach. Routine cytogenetics and DNA extractionin the British Isles: demonstration of a striking founder effect
would be performed simultaneously. The suspensionby microsatellite-generated haplotypes. Genome Res 6:92–101
from the cytogenetic harvest would be forwarded to theWijnen LMM, Meera Khan P (1982) Assignment of GPT to
FISH laboratory. Methylation analysis would be per-human chromosome 16. Cytogenet Cell Genet 32:327
Zhang K, Bither PP, Parl R, Donoso LA, Seidman JG, Seidman formed on an aliquot of the extracted DNA. Finally,
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FISH would be performed only on those cases with an all classical PWS patients—an additional three patients
with abnormal methylation require further clinical eval-abnormal methylation pattern. This seemed a logical
and cost-effective testing protocol. uation. AS was more problematic, as would be expected
on the basis of the more complex genetic etiology. OnlyBlood samples received in the laboratory were accom-
panied by a referral form. The requested amount was 51% of classical AS patients showed an abnormal meth-
ylation pattern—the expectation was 75%–80%10 ml, but frequently samples from babies were only 1–
3 ml, those from older children 5 ml. The blood sample (American Society of Human Genetics/American Col-
lege of Medical Genetics Test and Technology Transferwas split on arrival in the laboratory. An aliquot of 0.5
ml was retained for routine 72-h cytogenetic culture, Committee 1996)—and an additional four patients
need to be reassessed. FISH was not performed in 54followed by harvest and GTG banding. The remainder
was given to the molecular laboratory, and DNA was cases, representing a substantial saving among the 152
cases of nonclassical phenotype. On the other hand,extracted by a simple salting-out technique (Miller et al.
1988) and was stored. The suspension remaining after FISH was performed ﬁrst in 25 (35%) of the PWS pa-
tients and in 73 (55%) of the AS patients, for whom athe cytogenetic harvest was sent to the FISH laboratory
and was stored at 020C. A cytogenetic result was ob- normal methylation pattern was later found. This
‘‘early’’ FISH testing, welcomed by the referring doctor,tained, usually within 15 d, and, if this was normal, the
methylation test was perfomed on an aliquot of was unnecessary, offsetting the beneﬁt of the logical ap-
proach.the extracted DNA. For methylation analysis, enzymes
HindIII and HpaII were used with P32-labeled probe
Logistics of Multiple TestingPW71B (kindly donated by B. Horsthemke, Essen), by
standard Southern blotting techniques (Dittrich et al. In reviewing our results, we ﬁnd that several points
are worth highlighting. With respect to methylation1992). If the methylation pattern diagnosed PWS or AS,
then FISH was performed on slides redropped from the analysis, a number of problems were encountered in
establishing the laboratory; the blood specimens re-stored suspension, by use of probe SNRPN or probe
D15S10 (Oncor or Vysis). For cases not deleted by FISH, ceived for DNA extraction were frequently inadequate
(particularly in babies) once the requirements of cytoge-parents’ bloods were requested and DNA was extracted.
CA repeats for uniparental disomy were then performed netics had been met; the radioactive P32 was obtained
fortnightly; the methylation tests were batched (onceon all three specimens.
During the ﬁrst 12 mo, 204 patients were referred, every 3–4 wk), because of the variable numbers received
each week; occasionally the blood needed to be frozen71 for PWS and 133 for AS. Results are shown in table
1, together with a broad clinical evaluation. Both PWS and DNA was extracted later. Thus there were delays
in the methylation results, with turnaround time for aand AS were overdiagnosed, perhaps because of clini-
cian enthusiasm to further test unresolved cases. The result being 1–3 mo, depending on the need for a repeat
test, availability of fresh P32, and staff availability. Asmethylation test gave a characteristic abnormal result in
many as 50% of the methylation tests were repeated,
but one would expect this percentage to improve. On
Table 1 the other hand, the cytogenetic/FISH laboratory receives
many requests for FISH for a range of microdeletionResults of Diagnostic Testing for Patients Suspected
syndromes, so that these are processed at least once perto Have PWS or AS
week and there is no back log. The FISH result (routinely
TOTAL NO. OF PATIENTS WITH on 50 cells) was available in 2–3 d, and overall only
SYNDROME/NO. (% OF TOTAL) 5% of FISH tests needed to be repeated to obtain opti-
OF PATIENTS WITH CLASSICAL
mal quality.PHENOTYPEa
Coordinating the progress of specimens was the great-
PWS AS est task, even in our ‘‘ideal’’ setting. Considerable time
was spent in data entry, updating the progress of speci-
Referrals 71/17 (24) 133/35 (26) mens, obtaining clinical information, storage of suspen-
Methylation-pattern status:
sions, organizing blood recollection because of unsatis-Normal 51/0 111/17
factory DNA specimens, answering phone calls, andAbnormal 20/17 22/18
FISH status: educating clinicians about the testing protocol. The com-
Performed 55/. . . (77) 95/. . . (71) ponent of the coordination of multiple tests cannot be
Not performed 16/. . . (23) 38/. . . (29) ignored. In reality, we did not adhere to our desired
protocol very stringently—in many cases FISH was thea Diagnostic criteria for the PWS classical phenotype are from Holm
only test performed, and, in 95% of the cases in whichet al. (1993); consensus diagnostic criteria for AS are from Williams
et al. (1995). both tests were performed, the FISH test result was actu-
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ally available ﬁrst. The logistics of how multiple testing he or she is referred. They suggested a questionnaire, to
enhance the pick-up rate. The clinical acumen of thecan best be coordinated has not been discussed before.
referring doctors is important, and continuing education
The Costing of Tests is always a priority, but in cases of genuine doubt it
seems worthwhile to order the test. In our setting, clini-The most signiﬁcant factor in the costing of all tests
is the salary of the scientists performing the tests, plus cal input was available and useful in evaluating the pa-
tient but was more time consuming than initially imag-any supervisor/coordinator’s salary. These salary costs
are usually dependent on personnel gradings, and labo- ined. It would be simpler if two specimens of blood were
collected from the patient—one for cytogenetics andratories use staff at different academic/grading levels, so
they may not be directly comparable. The next major FISH and one for DNA studies. The results could be
correlated later. This would involve an additional collec-cost is that of the probes. Commercially available probes
need to be purchased on a regular basis and involve a tion cost and would defeat the aim of logical test pro-
gression on a single blood sample, but it would reducesubstantial capital outlay. Probes grown in-house are
frequently considered to be ‘‘free,’’ but a signiﬁcant staff the logistical costs considerably.
In conclusion, we consider the actual costs of the labo-component is required in the growing, purifying, and
labeling of these probes. A detailed cost analysis may ratory reagents to be immaterial. The stafﬁng and orga-
nizational costs are the major determinant in cost-effec-show the differences to be neglible. A further important
factor is the cost of laboratory overheads (e.g., water, tiveness. The recommendations of The American Society
of Human Genetics/American College of Medical Genet-electricity, land rates, maintenance, etc.), which, in some
cases, may not be directly billed to the laboratory. ics Test and Technology Transfer Committee (1996)—
namely, to make the maximum use of your resourcesIn the letter by Monaghan et al. (1997), a cost of
US$200.00 was given for a FISH test and a cost of and to remain ﬂexible—are eminently sensible. This is
now our policy.US$300.00 was given for a methylation test. Details of
how these costs were derived were not provided (nor
ARABELLA SMITH, TINA BUCHHOLZ,was it speciﬁed whether they represent either the amount
AND LISA ROBSONbilled to the patient or actual costs), so it is not possible
Department of Cytogeneticsto make valid comparisons with the costs incurred by
Royal Alexandra Hospital for Childrenthese tests in other laboratories.
Westmead, AustraliaThe actual cost of FISH in our laboratory is
AU$288.00/test (the exchange rate on 3 April 1997 was
AU$1.00 to US$0.7957). This comprises an average
AU$38.00 for reagents (depending on probe) and References
AU$250.00 for staff. This excludes overhead costs,
American Society of Human Genetics/American College ofborne by the hospital. To obtain an idea of the cost of
Medical Genetics Test and Technology Transfer Committee,a FISH test overall in Australia, a survey, commissioned
The (1996) Diagnostic testing for Prader-Willi andby the Australasian Society of Cytogeneticists, arrived
Angelman syndromes: report of the ASHG/ACMG Test andat a minimal cost of AU$250.00/test, if overhead labora-
Technology Transfer Committee. Am J Hum Genet 58:tory maintenance was not included, or AU$500.00, if
1085–1088
these costs were included. Chu CE, Cooke A, Stephenson JBP, Tolmie JL, Clarke B,
In our laboratory, the actual cost of methylation test- Parry-Jones WL, Connor JM, et al (1994) Diagnosis in
ing, including DNA extraction, with donated probe, is Prader-Willi syndrome. Arch Dis Child 71:441–
AU$276.00/test (comprising an average of AU$26.00 442
for reagents, plus stafﬁng and overhead factors similar Dittrich B, Robinson WP, Knoblauch H, Buiting K, Schmidt
K, Gillessen-Kaesbach G, Horsthemke B (1992) Molecularto those for FISH). An informal meeting, in association
diagnosis of the Prader-Willi and Angelman syndromes bywith the International Prader-Willi Syndrome Organisa-
detection of parent-of-origin speciﬁc DNA methylation intion Conference in Oslo in 1995, discussed costs of test-
15q11-13. Hum Genet 90:313–315ing. A ﬁnal ﬁgure was not forthcoming, but it was clear
Erdel M, Schuffenhauer S, Buchholz B, Barth-Witte U, Kochlfrom the delegates present that the methylation test us-
S, Utermann B, Duba HC, et al (1996) Routine screening foring DNA probes grown in-house was cheaper than a
microdeletions by FISH in 77 patients suspected of having
FISH test using commercial probes (authors’ unpub- Prader-Willi or Angelman syndromes using YAC clone
lished data). In our laboratory, the costs are similar for 273A2 (D15S10). Hum Genet 97:784–793
both tests. Holm VA, Cassidy SB, Butler MG, Hanchett JM,
The cost-effectiveness is another matter. Monaghan Greenswag LR, Whitman BY, Greenberg F (1993)
et al. (1997) show how this is related to the likelihood Prader-Willi syndrome: consensus diagnostic criteria.
Pediatrics 91:398–402of the patient actually having the condition for which
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Kubota T, Sutcliffe JS, Aradhya S, Gillesen-Kaesbach G, et al. (1996, p. 938) say that ‘‘the nomenclature used
Christian SL, Horsthemke B, Beaudet A, et al (1996) here is not related to that of Bailliet et al. (1994).’’ In
Validation studies of SNRPN methylation as a diagnos- light of these two comments, we think that it is worth-
tic test for Prader-Willi syndrome. Am J Med Genet 66: while to assess the soundness of Forster et al.’s argu-
77–80 ments.
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out
The A1/A2 and D1/D2 haplotypes used by Forster etprocedure for extracting DNA from human nucleated cells.
al. (1996) are differentiated by a base substitution inNucleic Acids Res 16:1215
mtDNA positions 16111 and 16271, respectively. OnMonaghan KG, Van Dyke DL, Feldman G, Wiktor A,
the other hand, our subgroups A1/A2 and D1/D2 dependWeiss L (1997) Diagnostic testing: a cost analysis for
on a base substitution at position 16519. Thus, in bothPrader-Willi and Angelman syndromes. Am J Hum Genet
60:244–247 reports haplotype grouping depends on a single transi-
Smith A, Prasad M, Deng Z-M, Robson L, Woodage T, Trent tion. Forster et al. (1996) indicate that the TrC transi-
RJ (1995) Comparison of high resolution cytogenetics, ﬂu- tion used by us is recurrent and, according to them,
orescence in situ hybridisation, and DNA studies to validate unsuited for phylogenetic use. Yet, the same authors,
the diagnosis of Prader-Willi and Angelman syndromes. despite ﬁnding that transitions at positions 16325 and
Arch Dis Child 72:397–402 16362 are also recurrent, use them for haplotyping and
Williams CA, Angelman H, Clayton-Smith J, Driscoll DJ, Hen-
phylogenetic reconstruction (Forster et al. 1996). More-drickson JE, Knoll JHM, Magenis RE, et al (1995)
over, Torroni et al. (1993), in table V of their report,Angelman syndrome: consensus for diagnostic criteria. Am
show that 3 of the 11 cases of Amerindians/Asians hav-J Med Genet 56:237–238
ing the founder haplotype B exhibit also the TrG transi-Young ID (1995) Diagnosing Prader-Willi syndrome. Lancet
tion at position 16111, which is a clear demonstration of345:1590
recurrence for this site. This is not surprising. Recently,
Address for correspondence and reprints: Dr. Arabella Smith, Department of Howell et al. (1996) made a direct appraisal of the muta-
Cytogenetics, Royal Alexandra Hospital for Children, Hawkesbury Rd, West- tion rate in human mtDNA and found an average of
mead 2145, Australia. E-mail: ellies@nch.edu.au
one nucleotide substitution every 25 generations. Ac- 1997 by The American Society of Human Genetics. All rights reserved.
0002-9297/97/6101-0035$02.00 cordingly, if this ﬁnding is conﬁrmed, most mitochon-
drial mutations would be expected to be recurrent.
Transitions at positions 16111 and 16271 produce
the loss of a Cac81 and a BfaI site, respectively. By
analyzing the data in the literature and by restricting
Am. J. Hum. Genet. 61:244–246, 1997 a series of A1/A2 and D1/D2 haplotypes by use of the
aforementioned enzymes, we have determined that
92%–95% of these haploforms can be identiﬁed as indi-Further Comments on the Characterization of
cated in table 1. The data in table 1 maintain the nomen-Founder Amerindian Mitochondrial Haplotypes
clature system proposed by us (Bailliet et al. 1994) and
To the Editor: used by Forster et al. (1996) but give a better deﬁnition
of the haplotypes.We have detected the presence of 8–10 founder mito-
chondrial haplotypes in extant Amerindian populations
(Bailliet et al. 1994; Bianchi et al. 1995), and we identi-
ﬁed four of these haplotypes by use of the acronyms
Table 1‘‘A1,’’ ‘‘A2,’’ ‘‘D1,’’ and ‘‘D2.’’ Easton et al. (1996) con-
ﬁrmed most of our ﬁndings and used the nomenclature
Characterization of A1/A2 and D1/D2 Mitochondrial Haplotypessystem proposed by us.
In the October 1996 issue of the Journal, Forster et al. STATUS FOR RESTRICTION ENZYME (POSITION)a
(1996) verify that the number of ancestral Amerindian
HAPLOTYPE HaeIII (663) Cac81 (16111) HaeIII (16517)mitochondrial haplotypes is greater than the four vari-
ants reported by Torroni et al. (1992); and they too
A1 / / /use the symbols A1, A2, D1, and D2 for identiﬁcation. A2 / 0 0
However, in their report, these authors state that ‘‘the
AluI (5176) BfaI (16271) HaeIII (16517)decision taken by Bailliet et al. (1994) and Bianchi et
al. (1995) to identify founding haplotypes according to
D1 0 / /16517 HaeIII status is therefore phylogenetically ques-
D2 0 0 0tionable, and we do not recommend the use of their
haplogroups or their nomenclature’’ (Forster et al. 1996, a A plus sign (/) denotes presence, and a minus sign (0) denotes
absence.p. 938). Moreover, in the legend to their ﬁgure 1, Forster
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